Category Archives: BioUtah News
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited; Provides Corporate Update
Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million. The combined, publicly traded company is operating under the name Clene Inc., and its common stock began trading on the NASDAQ Capital Market on […]
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). This first of its kind program is expected to improve patient outcomes and provide meaningful cost reductions for healthcare providers and […]
Early Vaccination Available for Some Life Science Industry Employees
We’ve received more information on channels for vaccine distribution with some positive developments
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform
Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain […]
Vertex Announces FDA Approvals for Expanded Use of Cystic Fibrosis Medicines
Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the CFTR gene. SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) also received approvals to include additional responsive mutations in people with CF ages 6 years and older and age 4 […]
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform. This new offering follows a fund raise in 2019 of more than $1.1 million via Netcapital. Proceeds from this latest campaign will further support the development […]
State of Utah Announces Updated Plans for Vaccine Distribution
Today the State of Utah released updated plans for First Wave of Phase 2 COVID-19 Vaccine Distribution. Notably the press release states that “Prioritization based on an individual’s employment status in certain industries is no longer being considered by the Unified Command group”.
Medsential Offering an FDA EUA Approved COVID Point of Care Antibody Rapid Test
Medsential has announced that it is now offering COVID-19 IgM/IgG rapid antibody tests to point of care providers and is able to meet high demand. The test has recently received FDA emergency use authorization. “We are thrilled to have a point of care rapid antibody test now available. We know hospitals, medical offices, and other […]
ELITech’s COVID, Flu, RSV Multiplex Test Receives CE Mark
ELITech Group recently announced its SARS-CoV-2 Plus Elite MGB Kit received CE marking and has been released. The test kit was developed to distinguish SARS-CoV-2 from other respiratory viruses, including influenza A/B and respiratory syncytial virus types A/B that may have similar symptoms. It runs on the firm’s Elite InGenius platform, as well as other […]
SDP Oncology Presents Data Evaluating Alvocidib in Patients with Acute Myeloid Leukemia and Other Updates on Development Programs at ASH 2020
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently presented new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in patients with MCL-1 dependent acute myeloid leukemia (AML). These results were presented at the 62nd American Society of Hematology Annual Meeting, which was held virtually December 5-8, […]
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia (AML) who have TP53 […]
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 2 of Cancer Study
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in patients with platinum-resistant ovarian cancer (PROC). The […]
